Enobosarm is a selective androgen receptor modulator (SARM) being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. The company achieved regulatory clarity from the FDA for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, with Phase 2b PLATEAU study planned to start Q1 2026.
Cyborg Score Rationale
Innovative therapy and robust patent protection position Veru to capture strong long-term growth in the expanding obesity market, with advancing clinical progress and regulatory clarity potentially accelerating commercialization while reducing funding risks. However, as a late-stage clinical biotech with limited revenue, execution risk remains material.
Top Insights
FDA guidance indicates ≥5% placebo-corrected incremental weight loss at 52 weeks or smaller weight difference with clinically meaningful physical function benefit may support approval.
Average analyst rating is "Strong Buy" with 12-month stock price target of $22.50, representing 772% upside from recent prices.
Recent capital markets activity includes underwritten public offering, 1-for-10 reverse stock split, and pursuit of Nasdaq compliance.
Sabizabulin being explored as a novel oral broad anti-inflammatory agent for atherosclerotic cardiovascular disease treatment, with compelling scientific rationale.
Named Competitors
Semaglutide — GLP-1 receptor agonist for weight management and diabetes
Tirzepatide — GIP/GLP-1 receptor agonist for weight management
VK2735 — Dual GLP-1/GCG receptor agonist in development for obesity
Recent Developments
(February 2026) Q1 fiscal 2026 results and clinical updates announced
(December 2025) FDA regulatory clarity achieved for enobosarm with Phase 2b PLATEAU study planned for Q1 2026
(August 2025) Selection of novel modified release oral enobosarm formulation following pharmacokinetic clinical study; 1-for-10 reverse stock split executed
Open the full interactive Veru Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.